• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Over $27M Bet On This Consumer Cyclical Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

    7/19/23 7:03:12 AM ET
    $GRIL
    $VBIV
    Restaurants
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRIL alert in real time by email

    The Dow Jones closed higher by more than 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    Muscle Maker

    • The Trade: Muscle Maker, Inc. (NASDAQ:GRIL) 10% owner Aggia FZ LLC acquired a total of 8,855,452 shares an average price of $3.12. To acquire these shares, it cost around $27.63 million.
    • What’s Happening: Muscle Maker amended its current Services Agreement with AGGIA LLC FZ.
    • What Muscle Maker Does: Muscle Maker Inc owns and operates three healthier-for-you restaurant concepts within its portfolio of companies: Muscle Maker Grill restaurants, SuperFit Foods meal prep and Pokemoto Hawaiian Poke restaurants.

    RocketFuel Blockchain

    • The Trade: RocketFuel Blockchain, Inc. (OTC:RKFL) CEO Peter M. Jensen acquired a total of 1,000 shares at an average price of $0.19. The insider spent around 185.
    • What’s Happening: RocketFuel announced a collaboration with Poncho Brotherz, a leading family-owned and operated farm-to-retail cannabis retail store.
    • What RocketFuel Blockchain Does: RocketFuel Blockchain Inc is a development-stage company that is in the process of developing check-out systems based upon blockchain technology and designed to increase speed, security, and ease of use.

    VBI Vaccines

    • The Trade: VBI Vaccines Inc. (NASDAQ:VBIV) Director Steven Gillis acquired a total of 609,090 shares at an average price of $1.65. To acquire these shares, it cost around $1 million.
    • What’s Happening: VBI Vaccines announced an $18 million public offering and a $3 million concurrent registered direct offering.
    • What VBI Vaccines Does: VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology.

     

    Check This Out: Investor Optimism Improves After Dow Rises For Seventh Straight Session

    Don’t forget to check out our premarket coverage here

    Get the next $GRIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRIL
    $VBIV

    CompanyDatePrice TargetRatingAnalyst
    VBI Vaccines Inc. New
    $VBIV
    11/11/2022$5.00 → $2.00Strong Buy → Outperform
    Raymond James
    VBI Vaccines Inc. New
    $VBIV
    3/8/2022$9.00 → $6.00Strong Buy
    Raymond James
    VBI Vaccines Inc. New
    $VBIV
    12/29/2021$7.00 → $6.00Buy
    Jefferies
    More analyst ratings

    $GRIL
    $VBIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    VBI Vaccines downgraded by Raymond James with a new price target

    Raymond James downgraded VBI Vaccines from Strong Buy to Outperform and set a new price target of $2.00 from $5.00 previously

    11/11/22 7:30:44 AM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James reiterated coverage on VBI Vaccines with a new price target

    Raymond James reiterated coverage of VBI Vaccines with a rating of Strong Buy and set a new price target of $6.00 from $9.00 previously

    3/8/22 7:08:44 AM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on VBI Vaccines with a new price target

    Jefferies resumed coverage of VBI Vaccines with a rating of Buy and set a new price target of $6.00 from $7.00 previously

    12/29/21 7:23:26 AM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRIL
    $VBIV
    SEC Filings

    View All

    VBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    8-K - VBI Vaccines Inc/BC (0000764195) (Filer)

    8/2/24 4:05:34 PM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Other Events

    8-K - VBI Vaccines Inc/BC (0000764195) (Filer)

    7/30/24 10:28:18 AM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VBI Vaccines Inc. New filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - VBI Vaccines Inc/BC (0000764195) (Filer)

    6/25/24 4:15:17 PM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRIL
    $VBIV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $GRIL
    $VBIV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $GRIL
    $VBIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VBI Vaccines Provides an Update on its Restructuring Proceedings

    VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided an update on the restructuring proceedings announced on July 30, 2024. U.S. Chapter 15 Filing On August 2, 2024, the United States Bankruptcy Court for the District of Delaware granted provisional relief under Chapter 15 of the U.S. Bankruptcy Code, and scheduled a further hearing to consider the recognition of the July 30, 2024, Ontario Superior Court of Justice (Commercial List) order ("Initial Order"), which granted the company protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended ("C

    8/2/24 4:05:00 PM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

    VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the Ontario Superior Court of Justice (Commercial List) ("Court") has issued an initial order ("Initial Order") granting the company protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended ("CCAA"). The Initial Order provides for, among other things: (i) a stay of proceeding in favour of VBI, (ii) approval of the DIP Loan (as described below), and (iii) the appointment of Ernst & Young Inc. ("EY") to serve as monitor ("Monitor") in the Court during the restructuring ("Restructuring Pro

    7/30/24 9:55:00 AM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VBI Vaccines Announces Results of Annual General Meeting

    VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 25, 2024 (the "Meeting"). The total number of common shares of the Company ("Common Shares") represented by shareholders ("Shareholders") present in person or represented by proxy at the Meeting was an aggregate of 13,879,327 Common Shares, representing 48.39% of VBI's issued and outstanding Common Shares as of the record date for the Meeting, April 26, 2024. The voting results with respect to each of the following eight dir

    6/25/24 4:15:00 PM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Errington David bought $3,986 worth of shares (10,000 units at $0.40), increasing direct ownership by 50% to 30,156 units (SEC Form 4)

    4 - Sadot Group Inc. (0001701756) (Issuer)

    12/12/23 3:41:18 PM ET
    $GRIL
    Restaurants
    Consumer Discretionary

    Black Jennifer Kay bought $5,200 worth of shares (10,000 units at $0.52), increasing direct ownership by 20% to 60,800 units (SEC Form 4)

    4 - Sadot Group Inc. (0001701756) (Issuer)

    12/1/23 9:39:35 AM ET
    $GRIL
    Restaurants
    Consumer Discretionary

    Errington David bought $9,859 worth of shares (17,000 units at $0.58), increasing direct ownership by 539% to 20,156 units (SEC Form 4)

    4 - Sadot Group Inc. (0001701756) (Issuer)

    11/28/23 10:12:25 AM ET
    $GRIL
    Restaurants
    Consumer Discretionary

    Shankar Ray Shiwan was granted 4,987 shares, increasing direct ownership by 97% to 10,151 units (SEC Form 4)

    4 - Sadot Group Inc. (0001701756) (Issuer)

    1/8/24 10:08:16 AM ET
    $GRIL
    Restaurants
    Consumer Discretionary

    Oh Na Yeon was granted 4,987 shares, increasing direct ownership by 97% to 10,151 units (SEC Form 4)

    4 - Sadot Group Inc. (0001701756) (Issuer)

    1/8/24 10:07:05 AM ET
    $GRIL
    Restaurants
    Consumer Discretionary

    Menchik Paul L was granted 13,171 shares, increasing direct ownership by 7% to 194,970 units (SEC Form 4)

    4 - Sadot Group Inc. (0001701756) (Issuer)

    1/8/24 9:43:19 AM ET
    $GRIL
    Restaurants
    Consumer Discretionary

    $GRIL
    $VBIV
    Financials

    Live finance-specific insights

    View All

    Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

    Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie

    3/22/24 7:00:00 AM ET
    $ANTX
    $VBIV
    $VIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    VBI Vaccines Reports Third Quarter 2023 Financial Results

    PreHevbrio (Hepatitis B Vaccine [Recombinant]) global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023 Continued execution across earlier-stage pipeline, including: Initiation of Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) patients Interim Phase 1 data announced for pan-coronavirus candidate, VBI-2901 Novel mRNA-launched eVLP platform technology announced VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the quarter ended September 30, 2023. "In Q3, we were focused on pip

    11/14/23 4:05:00 PM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results

    First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching patients with strong intrinsic anti-HBsAg responses for curative treatments to start before the end of 2023 Regulatory submissions and preparation for launches of PreHevbri® in APAC countries and regions are underway Near-term revenue opportunities with PreHevbri® and strong balance sheet supporting operations through 2026 Company to host earnings call on August 22 at 8:00 PM ET / August 23 at 8:00 AM HKT and an HBV R&D Day on August 24 from 1:00-2:30 PM HKT DURHAM, N.C. and BEIJING, Aug. 22, 2023 /

    8/22/23 10:00:00 AM ET
    $VBIV
    $VIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $GRIL
    $VBIV
    Leadership Updates

    Live Leadership Updates

    View All

    Brii Biosciences Provides Latest Clinical Development and Corporate Updates

    Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the

    7/5/23 7:18:00 PM ET
    $ANTX
    $VBIV
    $VIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Muscle Maker, Inc. Appoints Dr. Ahmed Khan to Board

    FORT WORTH, TX / ACCESSWIRE / June 14, 2023 / Muscle Maker, Inc. (MMI), the "Company" (NASDAQ:GRIL), today announced it has named Dr. Ahmed Khan to its Board of Directors. Sadot LLC generated net income for Muscle Maker of $9.9 million milestone which triggers the final three board nominations by Aggia LLC FZ as outlined in a service agreement reached on November 18, 2022. Dr. Khan is the third nomination to be named of the final three board member seats.Dr. Khan brings more than 15 years of background in research and development (R&D) and operations, with experience in various sectors, including sustainability in the form of waste management and the automotive areas. Most recently, Khan led

    6/14/23 10:15:00 AM ET
    $GRIL
    Restaurants
    Consumer Discretionary

    Muscle Maker, Inc. Appoints David Errington to Board

    FORT WORTH, TX / ACCESSWIRE / June 12, 2023 / Muscle Maker, Inc. (MMI), the "Company" (NASDAQ:GRIL), today announced it has named David Errington to its Board of Directors. Sadot LLC generated net income for Muscle Maker of $9.9 million milestone which triggers the final three board nominations by Aggia LLC FZ as outlined in a service agreement reached on November 18, 2022. Mr. Errington is the second nomination to be named of the final three board member seats.Errington brings more than 20 years of experience in Sustainability and Environmental Sector with 13 years regional expertise in the Gulf Cooperation Council, including KSA, Bahrain, Qatar, Kuwait, UAE and Oman. In his most recent rol

    6/12/23 10:00:00 AM ET
    $GRIL
    Restaurants
    Consumer Discretionary

    $GRIL
    $VBIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by VBI Vaccines Inc. New (Amendment)

    SC 13D/A - VBI Vaccines Inc/BC (0000764195) (Subject)

    4/17/24 4:16:49 PM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Muscle Maker Inc (Amendment)

    SC 13G/A - Sadot Group Inc. (0001701756) (Subject)

    2/14/24 2:32:14 PM ET
    $GRIL
    Restaurants
    Consumer Discretionary

    SEC Form SC 13D/A filed by VBI Vaccines Inc. New (Amendment)

    SC 13D/A - VBI Vaccines Inc/BC (0000764195) (Subject)

    11/17/23 6:59:27 PM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care